Purpose: Targeting human epidermal growth factor receptor 2 (HER2) therapy is currently considered as the standard treatment for HER2-positive (HER2 
Introduction
Previous studies have demonstrated that the human epidermal growth factor receptor 2 (HER2) signaling pathway is a critical driver of carcinogenesis and tumor progression in approximately 7% to 34% of total patients with gastric cancer (1) (2) (3) . Targeting HER2 combined with chemotherapy has been the first-line treatment for HER2-positive (HER2 þ ) advanced gastric cancer (1, 4) . However, only few patients with HER2
þ gastric cancer responded to the HER2-targeting agents. Recently, preliminary results of a phase III trials evaluating the efficacy of lapatinib, a dual tyrosine kinase inhibitor (TKI) targeting both HER2 and epithelial growth factor receptor (EGFR), in conjunction with cytotoxic chemotherapy for HER2 þ advanced or metastatic gastric cancer (LOGiC study) were released. Unfortunately, the addition of lapatinib to chemotherapy did not significantly improve OS, the primary endpoint, compared with chemotherapy alone. The median OS was 12.2 versus 10.5 months, respectively (HR, 0.91; 95% CI, 0.73-1.12; P ¼ 0.3492). The median PFS was 6.0 versus 5.4 months, response rate 53% versus 40% and duration of response 7.3 versus 5.6 months (5) . Based on the data from LOGiC study, the observed unsatisfactory survival prolongation could be explained by the limited initial response to lapatinib for patients with HER2 gastric cancer, for observing that addition of lapatinib only increased 13% response rate (from 40% to 53%; ref. 5 ). This situation also exists for trastuzumab in the ToGA trial. Addition of trastuzumab to chemotherapy only increased the overall response rate by 12.8% (from 34.5% to 47.3%; ref. 1) . Thus, understanding the potential molecular mechanism of the intrinsic resistance to lapatinib could be critical to identify patients who would be likely to respond to the agents and to set more efficient therapeutic procedures.
Bypass receptor tyrosine kinase (RTK) pathways activation is considered to be a widespread resistance-conferring mechanism to targeted therapy (6) . However, which RTKs determine intrinsic responsiveness to lapatinib in HER2 þ gastric cancer, and how it is modified by other RTKs, are seldom systematically studied before. This study searched for RTKs potentially mediating lapatinib unresponsiveness via an unbiased functional genetic screening approach, in which a siRNA library targeting most human RTKs and related growth factors was transfected into HER2 þ gastric cancer cells and the effects on lapatinib sensitivity were then analyzed. The candidate RTKs were validated and confirmed in a panel of HER2 þ cell lines. We identified that activation of MET, HER3, insulin-like growth factor receptor 1R (IGF1R), and INSR signaling pathways represent novel mechanisms underlying lapatinib unresponsiveness in HER2 þ gastric cancer treatment, mechanistically because of restimulating the shared downstream AKT or ERK signaling, as well as restimulating WNT signaling and epithelial-to-mesenchymal transition (EMT)-like process. Importantly, activation of HER3, MET, and IGF1R pathways were found to be particularly enriched in HER2 þ patients. This research helps to explain the intrinsic resistance to HER2-targeted agents in HER2 þ gastric cancer. On the basis of these findings, individualized lapatinib combination strategy with agents targeting to these enriched resistance-conferring receptors may achieve substantial benefits to patients.
Materials and Methods
Cell lines NCI-N87, HGC-27, AGS, and SGC-7901 human gastric cancer tumor cells were obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). MKN-45, MKN-28 gastric cancer cells, and nonmalignant gastric epithelial cell line GES-1 were from 3DBiopharm Biotech Co. Ltd. SKBR3, HCC1954, and BT-474 breast cancer cells were from Breast Cancer Institute of Fudan University (Shanghai, China). SNU-216 cells were from Medical College of Xiamen University (Fuzhou, China). Cell lines were tested and authenticated by short tandem repeat (STR) DNA profiling analysis. Cells were cultured in MEM (HGC-27), F12K medium (AGS), or RPMI 1640 medium containing 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin (Invitrogen) at 37 C in a humidified atmosphere with 5% CO 2 .
Drug preparations
Lapatinib (GW572016; Tykerb) was provided by GlaxoSmithKline. NVP-AEW541 was provided by Novartis Pharma. All other TKIs used were purchased from Selleck Chemicals. Recombinant human hepatocyte growth factor (HGF), IGF1, Neuregulin 1, Insulin, fms-Like Tyrosine Kinase 3 ligand, Glial Cell Line-Derived Neurotrophic Factor, and GDNF family receptor alpha 1 (GFRa1) were purchased from PeproTech. Compounds were dissolved in 100% dimethyl sulfoxide (DMSO; Sigma-Aldrich) and diluted with culture medium to the desired concentration, with a final DMSO concentration <0.2% (v/v). DMSO was also added to control cells in culture.
shRNA and RNAi screens NCI-N87 cells (1,000 per well) were plated in 96-well plates and infected 24 hours later with a retrovirus RNAi library encoding 53 human RTK and 27 related growth factors (3DBiopharm Biotech). Cells in each well were infected with a pool of 4 distinct shRNA targeting different sequences of the same target transcript and a total of 8 independent shRNAs were designed for each gene. Scrambled shRNA controls that do not target any human gene were used as a negative control. Forty-eight hours after initial transduction, half of the plates were treated with lapatinib 0.02 mmol/L and the other half were treated with 0.2% DMSO. Medium containing lapatinib or DMSO control were refreshed every 48 hours. Cells were cultured in drug-free medium and the viability was assessed 7 days after initial lapatinib exposure, using CCK-8 Cell Viability Assay (Dojindo Laboratories) per the manufacturer's instructions.
Data analysis: derivation of drug sensitivity and antagonism
To identify gene targets that increase lapatinib sensitivity or resistance, the sensitivity index (SI) was calculated as described previously (7) , and the individual effects of shRNAs or drug were taken into account. The viability effect of specific shRNA without drug versus the scrambled control shRNA was designated as Rc/Cc. The effect of the drug on the viability of control cells was designated as Cd/Cc. This enabled us to calculate the expected combined effect of shRNA and drug on cell viability (Rc/Cc Â Cd/Cc). The observed combined effects of drug and shRNA on cell viability versus untreated scrambled control shRNA-transfected cells was designated as Rd/Cc. Therefore, an index of antagonism or sensitivity for each shRNA was calculated as (Rc/Cc Â Cd/Cc) À (Rd/Cc). A positive SI score indicates a sensitizing effect and a negative SI score indicates antagonism to the treatment. In addition, in order for the SI to usefully predict antagonism or sensitivity, the effect of shRNA combination with lapatinib versus lapatinib alone was also taken into consideration. Thus, an additional criteria that Rd/Cd > 1.1 (for antagonistic shRNAs) and Rd/Cd < 0.9 (for sensitizing shRNAs) was also used for selecting hits in this study (7) .
Validation of RNAi screen
Three distinct siRNA species (Qiagen) targeting the same gene were used to revalidate hits from the initial screen. All siRNAs were transfected in 96-well plates using the HiperFect Transfection Reagent (Qiagen) following the manufacturer's reverse-transfection protocol. Briefly, siRNA (final concentration ¼ 5 nmol/L) was first added to 96-well plates and incubated with HiperFect Transfection Reagent to allow formation of transfection complexes, and 5 Â 10 4 per well N87 cells were then seeded. Scrambled control siRNA (Qiagen) was used as the negative control. At 24 hours following transfection, cells were treated with lapatinib 0.01 to 0.05 mmol/L or 0.2% DMSO alone. Cell viability was assessed 5 days later using CCK-8 Cell Viability Assay. The assay was performed in triplicate. The effect of gene silencing was determined by quantitative PCR.
Cell viability assay and combination data analysis
Assessment of cell viability was performed as follows. Cells were seeded at 5,000 cells per well in 96-well plates and incubated overnight. Cells were then treated with increasing concentrations of the indicated drugs for 72 hours. Treatments at each concentration were carried out in 6 replicate wells and repeated 3 times. Cell viability was determined using the Cell Counting Kit-8 (Dojindo Laboratories) according to the manufacturer's instructions. IC 50 was determined by using the nonlinear regression model in GraphPad Prism version 5.0 (GraphPad Software).
Combination effects on potency were evaluated using the combination index (CI) as described previously (8, 9) , using Calcusyn version 2.1 (Biosoft), and was derived from the original concept of Chou and Talalay (10) . In general, a CI value <0.9, 0.9-1.1, or >1.1 indicates synergy, additivity, or antagonism, respectively. CI/fractional effect curves represent the CI versus the fraction of cells affected/killed by drugs in combination.
Immunoprecipitation
Cells were lysed in buffer containing 10 mmol/L Tris (pH 7.5), 100 mmol/L NaCl, 1 mmol/L EDTA, 1% NP40, and protease and phosphatase inhibitor cocktails. HER2 was immunoprecipitated from total protein extracts (200 mg) overnight, washed in PBS-0.1% Tween 20 buffer, and immunoblotted to detect EGFR, HER3, MET, IGFIR, and INSR. Irrelevant IgG served as a negative control.
Immunoblotting analysis
Cell analyses by Western blot analysis were cultured in full serum. Cells were lysed in radioimmunoprecipitation assay buffer supplemented with complete protease inhibitor cocktail (Roche). Protein concentrations were determined using the BCA Protein Assay Kit (Biyotime). Antibodies against HER2, p-HER2, EGFR, p-EGFR, p-HER3, MET (25H2), p-MET (Tyr1234/1235), IGFIR b receptor, p-IGFIR b receptor (Tyr1135/1136), AKT, p-AKT (Ser473), p42/44 MAP kinase, p-p42/44 MAP kinase (Thr202/ Tyr204), PTEN, E-cadherin, vimentin, SNAIL, ZEB1, b-catenin, and p-GSK3b were purchased from Cell Signaling Technology. Antibody against HER3 was purchased from Thermo Fisher Scientific. Antibody against b-actin was purchased from The Jackson Laboratory. Blots were probed with indicated primary antibodies, then incubated with the horseradish peroxidase-conjugated secondary antibody and detected by enhanced chemiluminescence reagent (Pierce).
Colony-formation assay and growth curves
Colony-formation assay and growth curves were conducted as previously described (11) . Briefly, NCI-N87 cells were seeded at 2 Â 10 4 cells per well in triplicate in 12-well plates and cultured in the absence and the presence of the drug or drug combination for 2 weeks. After fixing the cells with 4% paraformaldehyde, cell numbers were quantified by staining the cells with 0.1% crystal violet (SigmaAldrich), extracting dye with 10% acetic acid, and determining the optical density at 600 nm.
Detection of apoptosis
Cell apoptosis was detected using the Annexin V-FITC Apoptosis Detection Kit (Invitrogen) according to the manufacturer's instructions (12) . Briefly, NCI-N87 tumor cells (3 Â 10 5 /mL) were cultured in 6-well plates and treated with lapatinib, lapatinib plus HGF/IGF1, or lapatinib plus HGF/ IGF1 and PF-04217903/NVP-AEW541 for 24 hours. Both floating and adherent cells were harvested and stained with Annexin V and propidium iodide (PI) and analyzed on a Cytomics FC 500 flow cytometer (Beckman Coulter) using CXP software (Beckman Coulter).
In vitro migration assays
Cell migration was analyzed by a BD Falcon Cell Culture Insert System (BD Biosciences) with 8-mm pores. For motility assays, 1 Â 10 5 SNU-216 cells were seeded into upper uncoated inserts, treated with lapatinib 0.05 mmol/L, or HGF 50 ng/mL, IGF1 100 ng/mL, NRG1 50 ng/mL, insulin 1,000 ng/mL. Cells were seeded in serum-free medium and translocated to 10% serum media for 30 hours. After removal of the nonmigrated cells, the remaining cells were fixed, stained, and analyzed by inverted microscopy. Migrated cell numbers were obtained by counting 6 random fields at Â200 magnification from each group of three independent experiments.
Growth inhibition assay in vivo
Six-week-old male athymic nude mice were purchased from the Shanghai Slac Laboratory Animal Co. Ltd., and randomized into 1 of 4 groups (n ¼ 8/group). Tumors were established in male nude mice by subcutaneous implantation of NCI-N87 tumor fragments ($ 2 Â 2 Â 2 mm) obtained from donor mice. Treatment started at 7 days after implantation (day 0) with either lapatinib (30 mg/kg, orally daily for 24 days), AEW-541 (30 mg/kg, orally daily for 24 days) or sterile PBS (orally daily for 24 days) or the combination of lapatinib and AEW-541 at the doses above. Tumor volumes were determined from caliper measurements of tumor length (L) and width (W) according to the formula LW 2 /2. Both tumor size and body weight were measured twice per week.
Patients and specimens
A total of 156 specimens of primary gastric adenocarcinomas were obtained by surgical resection between 2007 and 2010 at Shanghai Cancer Hospital, Fudan University (Shanghai, China). Samples were acquired with informed consent, under the protocol approved by Shanghai Cancer Hospital research ethics committee. Paraffin blocks were selected on the basis of the availability of suitable formalinfixed, paraffin-embedded tissue and complete clinicopathologic and follow-up data (154 samples). Patients' clinicopathologic characteristics are summarized in Supplementary Table S2 . Tumor staging was determined according to the tumor-node-metastasis classification system of the American Joint Committee on Cancer, 7th edition.
Tissue microarray and immunohistochemistry
Tissue microarrays were constructed in collaboration with Shanghai Biochip Co. Ltd., as described previously (13) . All samples from patients with gastric cancer were reviewed histologically after hematoxylin and eosin staining. Representative cores were taken from paraffin blocks, away from necrotic and hemorrhagic regions.
Primary antibodies used for immunohistochemical assays were commercially available: antibodies against p-HER3, EGFR, p-EGFR, p-MET (Tyr1234/1235), and PTEN were from Cell Signaling Technology. Antibodies against p-IGFIR receptor (Y1161) and IGFI receptor were from Abcam. An anti-HER2/neu (4B5) rabbit primary antibody and an anti-Total c-MET (SP44) rabbit monoclonal primary antibody were from Roche. Antibody against HER3 was from Thermo Fisher Scientific. Immunohistochemistry (IHC) of paraffin sections was carried out using a 2-step protocol (MaxVision HRP-Polymer Detection System) according to the manufacturer's instructions. Briefly, paraffin sections were deparaffinized and then rehydrated. After microwave antigen retrieval, endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxide. Nonspecific binding sites were blocked with PBS containing 10% normal goat serum. After staining with primary antibodies and peroxidase polymer-conjugated secondary antibody, sections were incubated with diaminobenzidine solution and counterstained with hematoxylin. Negative control slides without the primary antibodies were included for all samples.
Scoring system of immunostaining
Slides were independently evaluated by 2 investigators who were blinded to the clinical information. For HER2, EGFR, MET, and IGFIR staining, only tumor cell membrane staining was considered (14) . Immunostaining was scored according to a semiquantitative 4-grade scale as follows: 0, no staining; 1þ, incomplete circumferential staining; 2þ, complete circumferential staining; and 3þ, complete strong circumferential staining. HER3, p-HER3, p-EGFR, p-MET, and p-IGFR samples were scored as 0, absent; 1þ, weak; 2þ, moderate; and 3þ, strong, with consideration of both the proportion and the intensity of the staining pattern in tumor cytoplasm, membrane, or nucleus. Tumors with >10% of stained tumor cells were regarded as positive for each marker. Samples with a score of 1þ, 2þ, or 3þ were considered positive for all the markers (14-18) except HER2, for which scores of 0 and 1þ were considered to be negative according to the criteria recommended by Hofmann and colleagues Figure 1 . shRNA screen to identify pathways responsible for lapatinib unresponsiveness in the library representing most of the RTK receptors and related growth factors. A, all shRNAs that alter drug action were scored for the level of lapatinib sensitivity using the SI. A positive SI score is a measure of sensitization and a negative SI score is indicative of antagonism to treatment. In this study, SI > 0.0474 (upper quartile, the dashed line) was considered as promoting a strong drug-sensitizing phenotype. B, validation of pathways increasing lapatinib sensitivity using independent siRNAs. MET, IGF1R, HGF, IGF1, HER3, INSR, and FLT3 gene silencing shows significant enhancement of lapatinib effectiveness. NCI-N87 cells were transfected with 3 independent siRNAs targeting each gene or scrambled siRNA. Cell viability was measured using CCK-8 cell-proliferation assay after 5 days of drug exposure. The percentage of viable cells is shown relative to untreated scrambled controls. Data points indicate average of replicates of 3 and bars indicate SEM. Ã , P < 0.05 compared with the lapatinib-treated scrambled control group. C, confirmation of pathways conferring lapatinib resistance via corresponding ligands. Stimulation of MET, IGF1R, HER3, and INSR with their corresponding ligands HGF, IGF1, NRG1, and insulin promoted resistance to lapatinib in HER2 positive N87 cells. Combination usage of corresponding TKIs (PF-04217903, AEW-541, AZD8931, and GSK1904529A) with lapatinib reversed these ligand-induced resistances. Although stimulation of FLT3 or RET with their corresponding ligands FLT3 ligand or GDNF plus GFRa1 could hardly confer lapatinib resistance. Colony-formation assays were conducted for about 2 weeks and growth curves were performed according to quantification analysis. The percentage of viable cells was shown relative to untreated controls. Data points indicate average of replicates of 3 and bars indicate SEM. Ã , P < 0.05 compared with the lapatinib-treated control group.
(1, 3). For PTEN staining, scoring was performed as previously described (19) . The surrounding normal epithelium served as an internal control and tumor immunoreactivity was scored accordingly: 0, no immunoreaction; 1þ, reduced intensity of immunoreaction compared with normal epithelium, and 2þ, intensity equal to normal epithelium. Samples with a score of 0 or 1þ were considered negative and 2þ were positive.
Statistical analysis
Statistical analyses were performed with SPSS 18.0 software (SPSS) or with GraphPad Prism version 5.0 (GraphPad Software). Quantitative variables were analyzed by the Student t test or one-way ANOVA with Bonferroni posttest. The Pearson x 2 test or Fisher exact test was used to compare qualitative variables. Differences between cell viability and growth curves were analyzed by two-way ANOVA followed by the Bonferroni multiple comparison test. A two-tailed P value of <0.05 was considered statistically significant.
Results

RNAi screening for pathways responsible for lapatinib unresponsiveness
To identify a HER2 "addicted" cell line as the model for RNAi screening, intrinsic lapatinib sensitivity of 6 human gastric cancer cell lines (HGC-27, SGC-7901, AGS, NCI-N87, MKN-45, and MKN-28) were determined. Results indicated that HER2
þ NCI-N87 cells were more responsive to lapatinib in these cell lines, with a half-maximum inhibitory concentration (IC 50 ) at 0.05 mmol/L, compared with all other HER2-negative (HER2 À ) gastric cancer cell lines, with IC 50 equal to or more than 10 mmol/L ( Supplementary  Fig. S1A and S1B). Lapatinib treatment inhibited HER2 and EGFR activation in HER2þ NCI-N87 cells and blocked downstream signaling through the MAPK and AKT pathways in a dose-dependent manner (Supplementary Fig.  S1C ). Thus, HER2 "addicted" and lapatinib responsive NCI-N87 cell line represents an appropriate model for further investigation on lapatinib drug sensitivity.
To identify RTKs whose knockdown sensitize tumor cells to lapatinib treatment, NCI-N87 gastric cancer cells were transfected with a shRNA library targeting 53 human RTK genes, 27 related growth factors, and scrambled control shRNA. As described previously (7), SI was generated for each individual gene to identify proteins whose knockdown induce a drug-sensitive or antagonistic phenotype. A positive SI score indicates a sensitizing effect, whereas a negative SI score indicates antagonism to the treatment. All shRNA hits that changed lapatinib sensitivity and their SIs are shown in Fig. 1A ; SI > 0.0474 (upper quartile) was considered to promote a strong drug-sensitizing phenotype. The top 10 potent lapatinib sensitivity-promoting candidates are listed in Supplementary Table S1. A phenotype caused by at least 2 distinct siRNA species is usually required to avoid off-target effects (20) . To validate the specificity of the effects observed in shRNA screening, 6 of the most interesting RTK genes (MET, IGF1R, HER3, INSR, FLT3, and RET) from the most potent lapatinibsensitizing candidates and 2 related ligands (HGF and IGF1) were re-assayed using 3 additional siRNAs (Qiagen). Silencing of 7 target hits (MET, IGF1R, HGF, IGF1, HER3, INSR, and FLT3) via independent siRNAs significantly enhanced the effectiveness of lapatinib treatment (P < 0.05; Fig. 1B) , and thus were considered to be "on-target." Knockdown of each gene was confirmed by polymerase chain reaction (PCR) or Western blot analysis (Supplementary Fig. S2) .
To confirm the hypothesis that activation of these RTKs contributes to lapatinib resistance, NCI-N87 cells were treated with lapatinib (0-0.1 mmol/L) for 2 weeks, accompanied by the corresponding ligands or selective inhibitors for RTKs. As shown in Fig. 1C , ligand induced activation of MET, IGF1R, HER3, and INSR with HGF, IGF1, NRG1, and insulin resulted in a significantly increased number of lapatinib-resistant colonies (P < 0.05). Adding the corresponding TKI (PF-04217903, AEW-541, AZD8931, and GSK1904529A) to the cells reversed the ligand-induced resistance (P < 0.05). Notably, as there was no commercial available highly selective HER3 inhibitor and a multitarget inhibitor AZD8931 that targets EGFR, HER2, and HER3 was used to inhibiting HER3 in this study. Activation of FLT3 or RET by their corresponding ligands, FLT3 ligand or GDNF plus GFRa1, failed to induce lapatinib resistance in NCI-N87 cells. Ligands and TKIs' effects on the corresponding receptors were confirmed by Western blot analysis (Supplementary Fig. S3 ). Consistently, FLT3 and RET protein were hardly expressed in this line ( Supplementary Fig. S2 ) and no response to their ligand were observed (Supplementary Fig. 2A) , which may contributed to its significant intrinsic unresponsiveness to lapatinib. Indeed, inhibiting MET or IGF1R activation by PF-04217903 or AEW-541 significantly restored lapatinib effectiveness on proliferation in HCC1954 cells, which were associated with their further blocking the downstream AKT and ERK signaling (Fig. 2B) .
To confirm the causal relationship between ligandinduced activation of the 4 RTKs and lapatinib resistance, BT-474, SKBR3, SNU-216, and HCC1954 cells were also treated with the corresponding RTK ligands when exposed to lapatinib. As shown in Fig. 2C , similar with NCI-N87 gastric cancer cells, ligand-induced activation of HER3, MET, IGF1R, and INSR also significantly increased the number of lapatinib-resistant colonies in SNU-216 gastric cancer cells (P < 0.05). In breast cancer cell lines, not all RTKs were potent: in BT-474 and SKBR3 cells, activation of HER3 caused lapatinib resistance (P < 0.05); in HCC1954 cells, activation of HER3 and MET caused lapatinib resistance (P < 0.05).
Furthermore, Western blot analysis and co-immunoprecipitation analysis revealed that RTK activation-induced lapatinib resistance was well correlated with baseline overexpression of certain RTKs, but not associated with the distribution of heterodimers between certain RTK and HER2 receptor, especially in the case of HER3, MET, and IGF1R receptors ( Fig. 2D and Supplementary Table S2 ). For instance, MET-overexpressed NCI-N87, SNU-216, and HCC1954 cells could be rescued from lapatinib by HGFinduced MET activation, whereas IGF1R-overexpressed NCI-N87 and SNU-216 cells were rescued from lapatinib by IGF1. These results suggest that the RTK expression profile of tumors may inform the potential combination therapeutic targets in lapatinib treatment.
Collectively, MET, HER3, IGF1R, and INSR bypass RTK pathway activation were also found modulating lapatinib unresponsiveness in a panel of HER2 þ cancer cell lines, depending on their activation or expression status.
Activation of bypass RTKs attenuates lapatinibinduced apoptosis and cell motility suppression
Using FACS analysis, we found bypass RTKs activation conferred lapatinib resistance by rescuing cells from lapatinib-induced apoptosis. Adding HGF to lapatinib treatment in NCI-N87 cells significantly reduced cell apoptosis rate from 18.6% to 11.7% (P < 0.0001), whereas addition of PF-04217903 to lapatinib/HGF treatment largely restored lapatinib-induced apoptosis back to 17.2% (Fig. 3A) . Similarly, IGF1 cotreatment significantly reduced cell apoptosis rate from 18.1% to 8.5% (P < 0.001) and addition of NVP-AEW541 (AEW) completely restored, and even enhanced lapatinib-induced apoptosis to 26.7% (Fig. 3A) . NRG1 also showed the similar rescue effect on lapatinib-induced apoptosis ( Supplementary Fig. S4A ).
Consider that progression disease and treatment failure are often caused by tumor invasion and metastasis, rather than tumor growth in many cases, we assessed the potential effect of bypass RTKs in lapatinib-induced suppression of tumor motility, which is the first step in the cascade of tumor invasion and metastasis. Transwell analysis demonstrated that SNU-216 cells migration was significantly suppressed by lapatinib at a concentration of 0.05 mmol/L, which had little effect on cell viability (<10%). However, either HGF, IGF1, or NRG1 cotreatment significantly rescued SNU-216 cells from lapatinib-induced suppression of motility ( Fig. 3B and Supplementary Fig. S4B ). These data confirmed that activation of bypass RTKs also attenuate lapatinib-induced suppression of cell migration and may potentially facilitate tumor invasion and metastasis.
Western blot analysis explored the molecular mechanism underlying RTK-induced lapatinib unresponsiveness. As shown in Fig. 3C (Fig. 3C) .
Together, these data demonstrate that in MET and HER2 cooverexpressed gastric cancer cells, MET activation confers lapatinib resistance through restimulating the MAPK and AKT signaling pathways. Similarly, IGF1R activation induces lapatinib resistance by restoration of AKT signaling in HER2 and IGF1R co-overexpressed gastric cancer cells (Fig. 3D ). HER3 activation induces lapatinib resistance by restoration of AKT signaling in HER2 and HER3 co-overexpressed gastric cancer cells (Supplementary Fig. S4C ).
To further confirm the involvement of IGF1R signaling in lapatinib resistance, we constructed a constitutively active IGF1R vector. NCI-N87 cells were stably infected with an empty lentiviral vector, CD8-IGFR with a constitutive activity of IGF1R (13) or CD8-IGFR-YF with an IGF1R kinase-inactive mutation (provided by Dr. L. Xiong; ref. 14) . As expected, CD8-IGFR-N87 cells, but not CD8-IGFR-YF-N87 cells, have a constitutive autophosphorylation activity of the IGF1R receptor and resulted in a significant increase in the emergence of lapatinib-resistant colonies ( Supplementary Fig. S5A and  S5B) . Consistently, constitutive activation of IGF1R leaded to AKT activation even in the presence of lapatinib (Supplementary Fig. S5B ), again suggesting a role of the IGF1R-AKT axis in IGF1R signaling-induced lapatinib resistance.
To further clarify the mechanism underlying RTKs attenuating lapatinib-induced suppression of cell migration, we assessed their effects on key components of WNT pathway and EMT properties. Surprisingly, we found that both MET and IGF1R activation reversed lapatinib-induced p-GSK3b and b-catenin inhibition, and restored expression of EMTinducing transcription factors (EMT-TF), SNAIL and ZEB1, and leaded to vimentin re-expression ( Fig. 3C and D) . These data indicated that RTKs-induced WNT signaling activation and EMT-like properties may also be involved in conferring lapatinib resistance.
Synergistic effects of AEW541 and lapatinib in vitro and in vivo
To determine whether there is in vitro synergistic antitumor effect between lapatinib and IGF1R inhibitor NVP-AEW541, multiple drug analyses were conducted in IGF1R-overexpressed HER2
þ NCI-N87 cells. Addition of AEW541
to lapatinib resulted in a significant increase in cell growth toxicity when compared with either drug alone (P < 0.0001; Fig. 4A ). The CI value at the IC 50 was 0.88 AE 0.29. The CI/fractional effect curve showed that the synergistic effects between these 2 agents were getting stronger as the concentration increased (Fig. 4A) . Interestingly, greater synergistic effects were detected when the IGF1R pathway was activated by exogenous IGF1, with the CI value at the IC 50 decreasing to 0.58 AE 0.16 (Fig. 4B) . These data support the hypothesis that a combination strategy targeting both HER2 and IGF1R receptors in IGF1R-overexpressed HER2 þ gastric cancer cells could be more effective, especially when the 2 pathways are both activated. In vivo study further confirmed the efficacy of this combination strategy in xenografts model. Addition of AEW541 to lapatinib was found to significantly impair the growth of subcutaneously implanted NCI-N87 tumors when compared with either drug alone (Fig. 4C) . No significant differences were observed in animal body weight (Fig. 4D) 
Discussion
According to recently released data from phase II and phase III trials (5, 21) , more than 80% of HER2 þ gastric cancer tumors are actually unresponsive to lapatinib. However, because of the lack of systematic study, the mechanisms conferring intrinsic resistance to lapatinib are poorly defined in HER2 þ gastric cancer. Unlike in HER2 þ breast cancers, in which disorders in the PI3K pathway are considered to be the major cause of intrinsic and acquired resistance to anti-HER2 agents (11, 19) , the PI3K pathway seems less related with lapatinib resistance in gastric cancer, because according to our data or others' (22), PTEN loss was rarely found (3.7%) in patients with HER2 þ gastric cancer. Consistently, PIK3CA mutation was previously reported to occur in only 4% to 11% of gastric cancer tumors (23, 24) . Although in HER2 þ BC, PTEN loss, and PIK3CA mutation were previously reported up to 19% and 42%, respectively (25) . We hypothesis that lapatinib intrinsic resistance are more likely to be associated with activation of alternative RTK pathways and try to identify these responsible RTKs. Through screening 53 human RTKs and 27 related growth factors, we tested and validated 8 candidates and finally identified MET, HER3, IGF1R, and INSR as key pathways modulating intrinsic resistance to lapatinib in HER2 þ gastric cancer cell lines. These results were further verified in a panel of HER2 þ cell lines, depending on the expression and activation status of a certain RTK. Notably, HER3 was identified as a key mediator of lapatinib resistance in all tested HER2 þ cell lines. This finding was echoed by the report of trastuzumab study, in which the trastuzumab resistance in HER2-amplified breast cancer cells was considered to be related to HER3 expression and activation (26, 27) . Furthermore, we found that almost all (96.3%) HER2 þ gastric cancer tumors from 154 specimens have HER3 expression and most of them (81.5%) are Cross-talk between signaling pathways, that is, switching to an alternative bypass survival signaling when one pathway is blocked, is considered to be driven resistance to targeted therapy (30) . There could be cross-talk in multiple levels between the HER2/EGFR and MET or IGF1R pathways: first, receptors of these pathways form homodimers or heterodimers with each other and lead to transactivation with each other (31, 32) ; second, they share key downstream ERK or AKT signaling nodes. We found RTK activation-induced lapatinib resistance was more likely to be correlated with baseline overexpression of certain RTKs, rather than with the distribution of RTK-HER2 heterodimers in these HER2 þ cells, especially in the case of HER3, MET, and IGF1R receptors. Our data demonstrated that stimulated RTKs conferred lapatinib resistance by activating downstream ERK or AKT signaling directly, rather than through heterodimers transactivation. Importantly, we also found cross-talk between these RTKs signaling with the WNT pathway, which is well known of its critical role in regulating EMT process and maintaining stem cell-like properties (33, 34) . In this study, both MET and IGF1R activation facilitated cell migration by attenuating lapatinib-induced p-GSK3b and b-catenin inhibition, and restored expression of EMTinducing transcription factors, and finally restimulating EMT-like process. Recent studies have demonstrated that EMT plays a critical role not only in tumor metastasis but also in tumor recurrence and resistance and that it is tightly linked with the biology of cancer stem-like cells or cancer-initiating cells (35) . Our findings are important because, they indicate that WNT-induced EMT process activated by alternative RTKs may also be involved in conferring lapatinib resistance and are seldom reported before. Indeed, we found WNT signaling activation via WNT1 supplementation or transfected b-catenin overexpression could both induced EMT process and lead to lapatinib resistance, and WNT pathway inhibitor could reverse the resistance (unpublished data). Recently, Wilson and colleagues reported that most kinase "addicted" human cancer cells can be rescued from kinase inhibitors by exposing them to one or more RTK ligands, highlighting the extensive redundancy of RTKtransduced signaling in cancer cells and the potential role of widely expressed RTK ligands in innate and acquired resistance (6) . As alternative RTKs activation is considered to be a widespread resistance mechanism to targeted therapy, identifying the responsible RTKs becomes particularly important to overcome drug resistance. Using a functional RNAi screen, our study clearly demonstrates that activation of MET, HER3, and IGF1R/INSR signaling is responsible for lapatinib unresponsiveness in HER2 þ gastric cancer. Considering the high prevalence of these pathways activation in HER2 þ gastric cancer tumors, this may largely explain the limited response of HER2-targeted agents in gastric cancer, as observed in previous phase II and phase III clinical trials, and cotargeting EGFR/HER2 with responsible bypass receptors may significantly improve the efficacy of HER2-targeted agents.
In conclusion, this study highlights the power of "synthetic lethality" RNAi screens to identify potential RTKs conferring unresponsiveness and/or combination drug targets for lapatinib therapy. Our results confirmed the hypothesis that alternative activation of bypass pathways could be a novel mechanism conferring anti-HER2 resistance in gastric cancer. We believe that HER2 þ patients represent heterogeneous individuals with different sensitivities to anti-HER2 agents. HER2 monotherapy is not enough for those patients with activation of these pathways. This study may be helpful to implementation of combination targeting therapy on patients with HER2 þ gastric cancer.
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